Employees: 02 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 2010-01-05 (16 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: MAGNAC-LAVAL (87190), Haute-Vienne
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE MAUVY CECILE : revenue, balance sheet and financial ratios
PHARMACIE MAUVY CECILE is a French company
founded 16 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in MAGNAC-LAVAL (87190),
this company of category PME
shows in 2025 a net income positive of 80 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE MAUVY CECILE (SIREN 519261903)
Indicator
2025
2024
2023
2022
2021
2019
2018
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
79 848 €
77 748 €
103 284 €
141 648 €
113 536 €
74 693 €
86 821 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE MAUVY CECILE generates positive net income of 80 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2018-2025: 87 k€ -> 80 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
79 848 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 87%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
0.1%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
86.944%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2021
2022
2023
2024
2025
Debt ratio
67.956
53.951
19.897
11.978
4.442
0.278
0.1
Financial autonomy
54.332
59.615
76.6
81.364
82.611
83.724
86.944
Repayment capacity
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
0.12025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Excellent
In 2025, the debt ratio of PHARMACIE MAUVY CECILE (0.10) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
86.94%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Excellent+12 pts over 3 years
In 2025, the financial autonomy of PHARMACIE MAUVY CECILE (86.9%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 208.01. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2018
2019
2021
2022
2023
2024
2025
Liquidity ratio
327.877
351.295
307.782
297.397
199.226
174.24
208.008
Interest coverage
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
208.012025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Good+6 pts over 3 years
In 2025, the liquidity ratio of PHARMACIE MAUVY CECILE (208.01) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Positioning of PHARMACIE MAUVY CECILE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE MAUVY CECILE is estimated at
1 268 394 €
(range 860 738€ - 1 990 286€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
860k€1268k€1990k€
1 268 394 €Range: 860 738€ - 1 990 286€
NAF 5 année 2025
Valuation method used
Net Income Multiple
79 848 €
×
15.9x
=1 268 395 €
Range: 860 739€ - 1 990 286€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE MAUVY CECILE with other companies in the same sector:
Frequently asked questions about PHARMACIE MAUVY CECILE
What is the revenue of PHARMACIE MAUVY CECILE ?
The revenue of PHARMACIE MAUVY CECILE is not publicly disclosed (confidential accounts filed with INPI).
Is PHARMACIE MAUVY CECILE profitable?
Yes, PHARMACIE MAUVY CECILE generated a net profit of 80 k€ in 2025.
Where is the headquarters of PHARMACIE MAUVY CECILE ?
The headquarters of PHARMACIE MAUVY CECILE is located in MAGNAC-LAVAL (87190), in the department Haute-Vienne.
Where to find the tax return of PHARMACIE MAUVY CECILE ?
The tax return of PHARMACIE MAUVY CECILE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE MAUVY CECILE operate?
PHARMACIE MAUVY CECILE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart